[1] SIMMS K T,STEINBERG J,CARUANA M,et al.Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries,2020-99:a modelling study[J].Lancet Oncol,2019,20(3):394-407. [2] Cancer Genome Atlas Research Network,Albert Einstein College Of Medicine, Analytical Biological Services, et al. Integrated genomic and molecular characterization of cervical cancer[J]. Nature,2017,543(7645):378-384. [3] 武丽,黄千峰,纪存委,等.宫颈癌不同初筛方法检出率及随访质量评价[J].中国公共卫生,2018,34(10):1380-1382. [4] 李凌. 农村地区高危型人乳头瘤病毒(hr-HPV)感染状况分析及宫颈癌hr-HPV初筛后分流策略的研究[D].南昌:南昌大学,2020. [5] 李婷婷,王翠峰.高危型人乳头瘤病毒联合宫颈液基薄层细胞学检测在宫颈上皮内瘤变筛查中的应用价值[J].中国全科医学,2021,24(9):1106-1110. [6] 肖丽芳. TCT联合HPV检测对宫颈癌筛查的意义[J].现代诊断与治疗,2020,31(17):2771-2772. [7] 广东省卫生和计划生育委员会,广东省财政厅,广东省妇女联合会.关于印发广东省农村妇女“两癌”免费检查项目实施方案(2017—2019年)的通知[Z].2017. [8] 杨宝华,徐军,谢锋,等.医联体内宫颈疾病双向转诊模式的研究[J].中华健康管理学杂志,2019,13(5):421-426. [9] 武丽,吕霄,刘婷艳,等.广东省农村妇女宫颈癌筛查质量及问题探究[J].中国妇幼保健,2016,31(5):909-910. [10] SAWAYA G F,SMITH-MCCUNNE K,KUPPERMANN M.Cervical cancer screening:more choices in 2019[J].JAMA,2019,321(20):2018-2019. [11] OLUSOLA P,BANERJEE H N,PHILLEY J V,et al.Human papilloma virus-associated cervical cancer and health disparities[J].Cells,2019,8(6):622. [12] ZHAO S,ZHAO X L,HU S Y,et al.Distribution of high-risk human papillomavirus genotype prevalence and attribution to cervical precancerous lesions in rural North China[J].Chin J Cancer Res,2019,31(4):663-672. [13] 揭俊钦,金龙妹,陈丹妮,等.宫颈癌筛查方案的成本效果评价:基于江浙沪地区[J].中国卫生资源,2019,22(3):175-179,203. [14] 杨慧宾,揭俊钦,陈丹妮,等.基于筛查技术有效性的宫颈癌筛查方案成本效果的敏感性分析[J].中国卫生资源,2019,22(3):180-184.